Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.
No Data